1. Leadership
  2. Here

Bryan E. Roberts, PhD

Board Member

Bryan has served on the Element Biosciences board of directors since September of 2017. He joined Venrock in 1997, and is currently a Partner based in Venrock’s Palo Alto office. Bryan focuses on a broad range of healthcare investments.

Since joining Venrock, Bryan has partnered with early-stage entrepreneurs innovating across healthcare and life sciences. Bryan is currently involved with companies across therapeutics, genomics, and health tech, including Aledade, Devoted Health, Encoded Therapeutics, Included Health, Interdict, Kelonia Therapeutics, Moonlight Bio, Mythic Therapeutics, Lyra Health, SmithRx and Suki.ai. Past investments include 10x Genomics (NASDAQ: TXG), Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Fate Therapeutics (NASDAQ: FATE), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Receptos (acquired by Celgene), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan).

Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He received his B.A. from Dartmouth College.